You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨CRO板塊集體反彈,消息稱S 3558號議案被延後審議
港股市場CRO板塊集體反彈,其中,凱萊英、藥明生物升超5%,金斯瑞、藥明康德、泰格醫藥升超4%,康龍化成升超3%,昭衍新藥升超2%。有消息稱,此前一度讓CRO板塊集體大跌的S 3558號議案在昨晚的參議員國土安全委員會會議上被延後審議,委員會需要做進一步討論後再擇日審議。另外,摩根士丹利發表最新報吿認為,市場可能對美國出台生物技術限制法案反應過敏,並認為藥明康德股價對此反應過度,提供潛在機會。報吿指,即使該法案成為法律,亦只是限制接受聯邦資金的項目外判給海外公司。該行相信,藥明康德作為一家高性價比的服務提供商,可於生物製藥行業發展中得益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account